Cost-effectiveness of activated protein C in real-life clinical practice

Critical Care

Volumn 11, Issue , 2007, Pages

  Dhainaut, Jean François ^a   Payet, Stéphanie ^b   Vallet, Benoit ^c   França, Lionel ^b   Annane, Djillali ^d   Bollaert, Pierre Edouard ^e   Le Tulzo, Yves ^f   Runge, Isabelle ^g   Malledant, Yannick ^f   Guidet, Bertrand ^h   Le Lay, Katell ^b   Launois, Robert ^b  

^a René Descartes University ^*  (France)

^b REES France   (France)

^c UNIV LILLE   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g La Source Hospital   (France)

^h HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; ANTICOAGULANT AGENT; PROTEIN C;

ADULT; AGED; ARTICLE; BOOTSTRAPPING; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HOSPITALIZATION COST; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REGRESSION ANALYSIS; SEPSIS; COHORT ANALYSIS; ECONOMICS; FRANCE; HOSPITAL COST; HOSPITALIZATION; MIDDLE AGED; STATISTICS; SURVIVAL;

ANTICOAGULANTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROTEIN C; SEPSIS; SURVIVAL ANALYSIS;

EID: 35748929120     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6116     Document Type: Article

References (41)

1. Angus DC Linde-Zwirble WT Lidicker J Clermont G Carcillo J Pinsky MR Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002 11445675
2. Angus DC Wax RS Epidemiology of sepsis: An update Crit Care Med 2001, 29(Suppl):S109-S116. 10.1097/00003246-200107001-00035
3. Vincent JL Bihari DJ Suter PM Bruining HA White J Nicolas-Chanoine MH Wolff M Spencer RC Hemmer M The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee JAMA 1995, 274:639-644. 10.1001/jama.274.8.639 7637145
4. Brun-Buisson C Meshaka P Pinton P Vallet B EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units Intensive Care Med 2004, 30:580-588. 10.1007/s00134-003-2121-4 14997295
5. Davies A Green C Hutton J Chinn C Severe sepsis: A European estimate of the burden of disease in ICU [abstract] Intensive Care Med 2001: Suppl 2 S284. S284.
6. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001 11236773
7. Dhainaut JF Laterre PF Janes JM Bernard GR Artigas A Bakker J Riess H Basson BR Charpentier J Utterback BG Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial Intensive Care Med 2003, 29:894-903. 12712239
8. Manns BJ Lee H Doig CJ Johnson D Donaldson C An economic evaluation of activated protein C treatment for severe sepsis N Engl J Med 2002, 347:993-1000. 10.1056/NEJMsa020969 12324556
9. Angus DC Linde-Zwirble WT Clermont G Ball DE Basson BR Ely EW Laterre PF Vincent JL Bernard G van Hout B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis Crit Care Med 2003, 31:1-11. 10.1097/00003246-200301000-00001 12544986
10. Betancourt M McKinnon PS Massanari RM Kanji S Bach D Devlin JW An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures Pharmacoeconomics 2003, 21:1331-1340. 10.2165/00019053-200321180-00004 14750900
11. Fowler RA Hill-Popper M Stasinos J Petrou C Sanders GD Garber AM Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis J Crit Care 2003, 18:181-191. discussion 191-184 10.1016/ j.jcrc.2003.08.009 14595571
12. Neilson AR Burchardi H Chinn C Clouth J Schneider H Angus D Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany J Crit Care 2003, 18:217-227. 10.1016/ j.jcrc.2003.10.005 14691895
13. Davies A Ridley S Hutton J Chinn C Barber B Angus DC Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Anaesthesia 2005, 60:155-162. 10.1111/ j.1365-2044.2004.04068.x 15644013
14. Riou França L Launois R Le Lay K Aegerter P Bouhassira M Meshaka P Guidet B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Int J Technol Assess Health Care 2006, 22;101-108. 16673686
15. Wiedermann CJ When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated) Intensive Care Med 2006, 32:604. 10.1007/ s00134-006-0086-9 16508757
16. Briggs AH O'Brien BJ The death of cost-minimization analysis? Health Econ 2001, 10:179-184. 10.1002/hec.584 11252048
17. Hartz A Marsh JL Methodologic issues in observational studies Clin Orthop Relat Res 2003, 413:33-42. 10.1097/01.blo.0000079325.41006.95 12897594
18. Riou Franca L Launois R Le Lay K Aegerter P Bouhassira M Meshaka P Guidet B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Int J Technol Assess Health Care 2006, 22:101-108. 16673686
19. Normand ST Landrum MB Guadagnoli E Ayanian JZ Ryan TJ Cleary PD McNeil BJ Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores J Clin Epidemiol 2001, 54:387-398. 10.1016/ S0895-4356(00)00321-8 11297888
20. D'Agostino RB Jr Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 1998, 17:2265-2281. 10.1002/ (SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 9802183
21. Yanovitsky I Zanutto E Hornik R Estimating causal effects of public health education campaigns using propensity score methodology Eval Program Planning 2005, 28:209-220. 10.1016/j.evalprogplan.2005.01.004
22. Mayo Clinic College of Medicine http://mayoresearch.mayo.edu/mayo/ research/biostat/upload/match.sas
23. Aegerter P Auvert B Buonamico G Sznajder M Beauchet A Guidet B le Gall JR CubRea Organization and quality control of a clinical database on intensive care medicine in central and suburban Paris [in French] Rev Epidemiol Sante Publique 1998, 46:226-237. 9690289
24. Sznajder M Aegerter P Launois R Merliere Y Guidet B CubRea A cost-effectiveness analysis of stays in intensive care units Intensive Care Med 2001, 27:146-153. 10.1007/s001340000760 11280626
25. Institut National de la Statistique et des Etudes Economiques (INSEE) http://www.insee.fr/fr/indicateur/achatfranc.htm
26. Efron B Tibshirani RJ An Introduction to the Bootstrap New York, NY: Chapman & Hall/CRC 1993
27. Institut National des Etudes Démographiques (INED) http://www.ined.fr/population-en-chiffres/france/index.html
28. Quartin AA Schein RM Kett DH Peduzzi PN Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group JAMA 1997, 277:1058-1063. 10.1001/ jama.277.13.1058 9091694
29. Granja C Teixeira-Pinto A Costa-Pereira A Quality of life after intensive care - evaluation with EQ-5D questionnaire Intensive Care Med 2002, 28:898-907. 10.1007/s00134-002-1345-z 12122528
30. Hurel D Loirat P Saulnier F Nicolas F Brivet F Quality of life 6 months after intensive care: Results of a prospective multicenter study using a generic health status scale and a satisfaction scale Intensive Care Med 1997, 23:331-337. 10.1007/s001340050336 9083237
31. Hoch JS Briggs AH Willan AR Something old, something new, something borrowed, something blue: A framework for the marriage of health econometrics and cost-effectiveness analysis Health Econ 2002, 11:415-430. 10.1002/hec.678 12112491
32. van Hout BA Al MJ Gordon GS Rutten FF Costs, effects and C/E-ratios alongside a clinical trial Health Econ 1994, 3:309-319. 10.1002/ hec.4730030505 7827647
33. Le Gall JR Lemeshow S Saulnier F A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study JAMA 1993, 270:2957-2963. 10.1001/jama.270.24.2957 8254858
34. Le Gall JR Klar J Lemeshow S Saulnier F Alberti C Artigas A Teres D The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group JAMA 1996, 276:802-810. 10.1001/jama.276.10.802 8769590
35. Annane D Sebille V Charpentier C Bollaert PE Francois B Korach JM Capellier G Cohen Y Azoulay E Troche G Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock JAMA 2002, 288:862-871. 10.1001/jama.288.7.862 12186604
36. Anti-infective Advisory Committee Clinical Review: Drotrecogin Alfa (Activated) [Recombinant Human Activated Protein C (rhAPC)] Xigris, BLA# 125029/0 Rockville, MD. Rockville, MD: Food and Drug Administration 2001.
37. Levy H Laterre PF Bates B Qualy RL Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated) Crit Care 2005, 9:R502-R507. 1297614 16277711 10.1186/cc3778
38. Ely EW Laterre PF Angus DC Helterbrand JD Levy H Dhainaut JF Vincent JL Macias WL Bernard GR Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis Crit Care Med 2003, 31:12-19. 10.1097/00003246-200301000-00002 12544987
39. Vincent JL Bernard GR Beale R Doig C Putensen C Dhainaut JF Artigas A Fumagalli R Macias W Wright T Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment Crit Care Med 2005, 33:2266-2277. 10.1097/01.CCM.0000181729.46010.83 16215381
40. Vincent JL O'Brien J Jr Wheeler A Wittebole X Garg R Trzaskoma BL Sundin DP Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis Crit Care 2006, 10:R74. 1550949 16684364 10.1186/cc4909
41. Carlet J Prescribing indications based on successful clinical trials in sepsis: A difficult exercise Crit Care Med 2006, 34:525-529. 10.1097/ 01.CCM.0000198329.85851.8E 16424736